

SUNZEN BIOTECH BERHAD

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2023**

		Current Quarter Ended 31.03.2023 (Unaudited) RM'000	Corresponding Quarter Ended 31.03.2022 (Unaudited) RM'000	Current Year-To-Date Ended 31.03.2023 (Unaudited) RM'000	Corresponding Year-To-Date Ended 31.03.2022 (Unaudited) RM'000
Revenue	A8	23,035	28,432	23,035	28,432
Operating profit		6,002	6,936	6,002	6,936
Operating expenses		(3,883)	(4,724)	(3,883)	(4,724)
Share of loss of associate		(21)	-	(21)	-
Finance costs		(62)	(52)	(62)	(52)
Profit before tax	B2, B3	2,036	2,160	2,036	2,160
Income tax expense	B7	(789)	(837)	(789)	(837)
Profit for the financial period		1,247	1,323	1,247	1,323
Other comprehensive income/(expense), net of tax					
<i>Items that may be reclassified subsequently to profit or loss</i>					
Foreign currency translation		(11)	(21)	(11)	(21)
		(11)	(21)	(11)	(21)
Total comprehensive income		1,236	1,302	1,236	1,302
Profit attributable to:					
Equity holders of the company		1,074	741	1,074	741
Non-controlling interests		173	582	173	582
		1,247	1,323	1,247	1,323
Total comprehensive income attributable to:					
Equity holders of the company		1,067	720	1,067	720
Non-controlling interests		169	582	169	582
		1,236	1,302	1,236	1,302
Earnings per ordinary share (sen)	B14				
-Basic		0.15	0.12	0.15	0.12
-Diluted		0.15	0.11	0.15	0.11

Note:

1) The above condensed consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2022 and the accompanying explanatory notes attached to the interim financial statements.

SUNZEN BIOTECH BERHAD

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2023**

	As At Financial Period Ended 31.03.2023 (Unaudited) RM'000	As At Financial Year Ended 31.12.2022 (Audited) RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	46,108	46,459
Right-of-use assets	263	347
Investment property	500	500
Trade receivables	55,566	55,390
Intangible asset	2,853	2,853
Investment in associate	469	-
	105,759	105,549
Current assets		
Inventories	9,645	11,329
Trade receivables	13,034	20,405
Other receivables, deposits and prepayments	1,114	1,088
Tax recoverable	308	348
Fixed and short term deposits with licensed banks	4,304	3,277
Cash and bank balances with licensed banks and other financial institution	11,929	8,961
	40,334	45,408
Total current assets	40,334	45,408
TOTAL ASSETS	146,093	150,957
EQUITY		
Share capital	A6 110,258	110,221
Treasury shares	A6 (2,956)	(2,956)
Share option reserve	7,468	7,483
Retained earnings/(Accumulated losses)	803	(271)
Revaluation reserve	15,647	15,647
Merger deficit	(8,397)	(8,397)
Currency translation reserve	147	154
Total equity attributable to equity holders of the Company	122,970	121,881
Non-controlling interests	7,997	7,828
TOTAL EQUITY	130,967	129,709
LIABILITIES		
Non-current liabilities		
Lease Liabilities	339	263
Deferred tax liabilities	3,558	3,569
Loans and borrowings	4,459	4,492
Other payables	51	51
	8,407	8,375
Current liabilities		
Trade payables	3,761	9,205
Other payables	2,238	3,036
Lease Liabilities	200	260
Loans and borrowings	130	129
Tax payable	390	243
	6,719	12,873
TOTAL LIABILITIES	15,126	21,248
TOTAL EQUITY AND LIABILITIES	146,093	150,957
Net assets per ordinary share (RM) attributable to equity holders of the Company	0.17	0.17

Notes:

- 1) The above condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2022 and the accompanying explanatory notes attached to the interim financial statements.
- 2) The net assets per share attributable to equity holders of the Company is calculated based on net assets value divided by the number of ordinary shares in issue at the end of the reporting period of 704,743,359 (2022: 704,603,359) excluding treasury shares of 15,937,300 (2022: 15,937,300).

SUNZEN BIOTECH BERHAD

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2023**

	← Attributable to equity holders of the Company →										Total Equity RM'000	
	Share Capital RM'000	Treasury Shares RM'000	Warrants Reserve RM'000	Share Option Reserve RM'000	Revaluation Reserve RM'000	Merger Deficit RM'000	Currency Translation Reserve RM'000	Retained earnings/ (Accumulated Losses) RM'000	Total RM'000	Non- Controlling Interests RM'000		
Quarter ended 31 March 2023 (Unaudited)												
Balance at 1 January 2023	110,221	(2,956)	-	7,483	15,647	(8,397)	154	(271)	121,881	7,828	129,709	
Profit for the financial period	-	-	-	-	-	-	-	1,074	1,074	173	1,247	
Other comprehensive income/(expense), net of tax for the financial period:												
- Foreign currency translation	-	-	-	-	-	-	(7)	-	(7)	(4)	(11)	
Total comprehensive income/(expense) for the financial period	-	-	-	-	-	-	(7)	1,074	1,067	169	1,236	
Issuance of shares pursuant to share options exercised	37	-	-	(15)	-	-	-	-	22	-	22	
Balance at 31 March 2023	110,258	(2,956)	-	7,468	15,647	(8,397)	147	803	122,970	7,997	130,967	
Quarter ended 31 March 2022 (Unaudited)												
Balance at 1 January 2022	108,177	(956)	-	7,674	15,683	(8,397)	(6)	(4,077)	118,098	7,370	125,468	
Profit for the financial period	-	-	-	-	-	-	-	741	741	582	1,323	
Other comprehensive income/(expense), net of tax for the financial period:												
- foreign currency translation	-	-	-	-	-	-	(21)	-	(21)	-	(21)	
Total comprehensive income/(expense) for the financial period	-	-	-	-	-	-	(21)	741	720	582	1,302	
Issuance of shares pursuant to share options exercised	596	-	-	(240)	-	-	-	-	356	-	356	
Subscription of shares of a subsidiary by non-controlling interest	-	-	-	-	-	-	-	-	-	40	40	
Share option granted under Share Issuance Scheme	-	-	-	200	-	-	-	-	200	-	200	
Share options lapsed	-	-	-	(8)	-	-	-	8	-	-	-	
Balance at 31 March 2022	108,773	(956)	-	7,626	15,683	(8,397)	(27)	(3,328)	119,374	7,992	127,366	

Note:

1) The above condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2022 and the accompanying explanatory notes attached to the interim financial statements.

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2023**

	Current Year To Date Ended 31.03.2023 (Unaudited) RM'000	Corresponding Year To Date Ended 31.03.2022 (Unaudited) RM'000
Cash flows from operating activities		
Profit before tax	2,036	2,160
Adjustments for:-		
Amortisation of intangible assets	-	9
Depreciation of:		
- property, plant and equipment	545	547
- right-of-use assets	61	77
Dividend income	(1)	(9)
Employee benefit expenses-Share Issuance Scheme	-	200
Impairment loss on receivables	43	38
Interest income	(12)	(8)
Interest expense	58	46
Inventories written down	104	155
Inventories written off	55	57
Reversal of impairment loss on receivables	(211)	(10)
Reversal of inventories written down	(39)	(194)
Share of loss of associate	21	-
Unrealised gain on foreign exchange	(44)	(13)
Operating profit before working capital changes	2,616	3,055
Decrease in inventories	1,574	467
Decrease/(Increase) in trade and other receivables	7,321	(17,011)
Decrease in trade and other payables	(6,191)	(33)
Cash from/(for) operations	5,320	(13,522)
Income tax paid	(658)	(239)
Income tax refunded	46	172
Interest paid	(55)	(46)
Net cash from/(for) operating activities	4,653	(13,635)
Cash flows from/(for) investing activities		
Dividend received	1	9
Interest received	12	8
Purchase of property, plant and equipment	(79)	(430)
Net cash for investing activities	(66)	(413)
Cash flows from/(for) financing activities		
Proceeds from issuance of shares to non-controlling interest	-	40
Proceeds from issuance of shares pursuant to share options exercised	22	356
Repayment of term loans	(27)	(33)
Repayment of lease liabilities	(80)	(43)
Investment in associate	(490)	-
Net cash (for)/from financing activities	(575)	320
Net increase/(decrease) in cash and cash equivalents	4,012	(13,728)
Cash and cash equivalents at beginning of the financial period	12,238	47,222
Foreign exchange difference	(17)	(10)
Cash and cash equivalents at end of the financial period	16,233	33,484
Cash and cash equivalents comprise:		
Fixed and short term deposits with licensed banks	4,304	14,333
Cash and bank balances with licensed banks and other financial institution	11,929	19,151
	16,233	33,484

Note:

1)The above condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2022 and the accompanying explanatory notes attached to the interim financial statements.

SUNZEN BIOTECH BERHAD

[Registration No. 200501003843 (680889-W)]

(Incorporated in Malaysia)

NOTES TO THE INTERIM STATEMENTS FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2023

A. NOTES PURSUANT TO THE MALAYSIAN FINANCIAL REPORTING STANDARD 134 (MFRS 134): INTERIM FINANCIAL REPORTING

A1. Basis of reporting preparation

The unaudited interim financial statements have been prepared in accordance with the Malaysian Financial Reporting Standards (“MFRS”) 134: “Interim Financial Reporting” issued by the Malaysian Accounting Standards Board (“MASB”) and Chapter 9, Part K of the Listing Requirements of Bursa Malaysia Securities Berhad (“Bursa Securities”) for the ACE Market (“ACE LR”). The unaudited interim financial statements should be read in conjunction with the audited annual financial statements of the Group for the financial year ended 31 December 2022.

The following MFRS and amendments that have been issued by the MASB are not yet effective for adoption by the Group.

MFRSs and Amendments to MFRSs effective for financial periods beginning on or after 1 January 2023

MFRS 17*	Insurance contracts
Amendments to MFRS 17*	Insurance contracts
Amendments to MFRS 17*	Insurance contracts: Initial application of MFRS 17 and MFRS9 - comparative information
Amendments to MFRS 101	Presentation of financial statements: Classification of liabilities as current or non-current
Amendments to MFRS 101	Presentation of financial statements: Disclosure of accounting policies
Amendments to MFRS 108	Accounting policies, changes in accounting estimates and errors: Definition of accounting estimates
Amendments to MFRS 112	Income taxes: Deferred tax related to assets and liabilities arising from a single transaction

MFRSs and Amendments to MFRSs effective for financial periods beginning on or after 1 January 2024

Amendments to MFRS 16	Leases: Lease liability in a sale and leaseback
Amendments to MFRS 101	Presentation of financial statements: Non-current liabilities with covenants

A1. Basis of reporting preparation (Cont'd)

Amendments to MFRSs effective date yet to be confirmed

Amendments to MFRS 10 and MFRS 128	Consolidated financial statements and investment in associates and joint ventures: Sale or contribution of assets between an investor and its associate or joint venture
------------------------------------	--

* Not applicable to the Group's and the Company's operation

The initial application of the above standard and amendments is not expected to have any material financial impact to the financial statement of the Group upon its adoption.

A2. Auditors' report on preceding annual financial statements

The audited financial statements of the Company and its subsidiaries for the FYE 31 December 2022 were not subjected to any qualification.

A3. Seasonal or cyclical factors

Sales performance of TCM segment, which involves herbal foods and beverages, traditional Chinese medicines and edible bird's nest, is partly impacted by seasonal factor.

A4. Items of unusual nature and amount

There were no items affecting assets, liabilities, equity, net income or cash flows that were unusual because of their nature, size or incidence during the current quarter under review.

A5. Material changes in estimates

There were no material changes in estimates of amounts reported that will have a material effect in the current quarter under review.

A6. Issuances, cancellations, repurchase, resale and repayments of debt and equity securities

For the current quarter ended 31 March 2023, additional 140,000 ordinary shares were issued pursuant to Share options exercised under Share Issuance Scheme, bringing the total number of ordinary shares in issue to 720,680,659, that is inclusive of 15,937,300 treasury shares.

A7. Dividend paid

There was no dividend paid in the current quarter under review.

A8. Segmental information

	Current Quarter Ended 31 March 2023 RM'000	Corresponding Quarter Ended 31 March 2022 RM'000	Current Year-To-Date Ended 31 March 2023 RM'000	Corresponding Year-To-Date Ended 31 March 2022 RM'000
Revenue				
Manufacturing and trading of animal health products (“AH”)	651	1,362	651	1,362
Traditional Chinese medicine, herbal health foods and beverages, edible bird’s nest (“TCM”)	19,066	25,288	19,066	25,288
Loan financing	3,318	1,782	3,318	1,782
Total	23,035	28,432	23,035	28,432

A9. Valuation of property, plant and equipment

Revaluation of the Group’s freehold lands and buildings has been brought forward without any amendments from the financial statement for financial year ended 31 December 2022.

A10. Capital commitments

Capital commitments which have been authorised but not provided for in the interim financial statements under review are as follows:

	31 March 2023 RM'000	31 March 2022 RM'000
Acquisition of property, plant and equipment	-	332

A11. Recurrent Related Party Transaction

There were no recurrent related party transactions in the current quarter under review.

A12. Material subsequent event after the Reporting Period

There were no material events subsequent to the end of the current quarter that have not been reflected in the financial statements, which are likely to substantially affect the current quarter results.

A13. Changes in the Composition of the Group

There were no changes in the corporate structure of the Group since the previous reporting date.

A14. Contingent Liabilities

	31 March 2023 RM'000	31 March 2022 RM'000
Unsecured Corporate Guarantee to financial institutions for banking facilities granted to subsidiaries	4,589	4,714

B. ADDITIONAL INFORMATION REQUIRED UNDER THE ACE LR

B1. Review of performance of the Company and its principal subsidiaries for the current quarter and financial year-to-date

	Current Quarter Ended 31 March 2023 RM'000	Corresponding Quarter Ended 31 March 2022 RM'000	Current Year-To-Date Ended 31 March 2023 RM'000	Corresponding Year-To-Date Ended 31 March 2022 RM'000
Revenue	23,035	28,432	23,035	28,432
Profit before tax	2,036	2,160	2,036	2,160

The Group reported 18.96% lower in revenue of RM23.04 million for the current quarter under review compared to RM28.43 million in the corresponding quarter, mainly due to the decrease in both contract manufacturing orders for TCM products and export sales of edible bird's nest ("TCM segment") as well as the decrease in demand for animal health products ("AH segment") in the current quarter, which have offset the increase in revenue contribution from loan financing segment.

The Group registered a lower pre-tax profit of approximately RM2.04 million in the current quarter although a much higher profit contributed from the loan financing business, compared to RM2.16 million in the previous year mainly due to the decrease in profit contribution from TCM segment on lower revenue achieved in the current quarter.

B2. Review of performance of the operating segments of the Company and its principal subsidiaries for the current quarter and financial year-to-date

	Current Quarter Ended 31 March 2023 RM'000	Corresponding Quarter Ended 31 March 2022 RM'000	Current Year-To-Date Ended 31 March 2023 RM'000	Corresponding Year-To-Date Ended 31 March 2022 RM'000
Revenue				
Manufacturing and trading of animal health products (“AH”)	651	1,362	651	1,362
Traditional Chinese medicines, herbal foods and beverages, edible bird’s nest (“TCM”)	19,066	25,288	19,066	25,288
Loan financing	3,318	1,782	3,318	1,782
Total revenue	23,035	28,432	23,035	28,432
Results				
Manufacturing and trading of animal health products	(1,633)	(1,434)	(1,633)	(1,434)
Traditional Chinese medicines, herbal foods and beverages, edible bird’s nest	609	2,201	609	2,201
Loan financing	3,060	1,393	3,060	1,393
Profit before tax	2,036	2,160	2,036	2,160

B2. Review of performance of the operating segments of the Company and its principal subsidiaries for the current quarter and financial year-to-date (Cont'd)

AH segment

Achieved a revenue of RM0.65 million in the current quarter, decreased by 52.21% compared to RM1.36 million in the corresponding quarter, mainly attributable to sales orders for animal health products reduced considerably as partly impacted by African Swine Fever (ASF), which posed a threat to swine farms.

The segment posted 13.99% higher pre-tax loss of RM1.63 million in the current quarter, against RM1.43 million pre-tax loss in the corresponding quarter.

TCM segment

Achieved 24.59% lower in revenue for the current quarter to RM19.07 million from RM25.29 million in the corresponding quarter, mainly due to sales orders for contract manufacturing service recorded relatively reduced compared to the corresponding quarter and export sales of edible bird's nest posted lower in the current quarter.

The segment registered a pre-tax profit of RM0.61 million in the current quarter, 72.27% lower as compared to RM2.20 million pre-tax profit posted in the corresponding quarter, mainly impacted by lower profit contribution on lower revenue achieved in the current quarter.

Loan financing segment

Posted a significant increase in revenue of RM3.32 million for the current quarter relative to RM1.78 million in the corresponding quarter, mainly due to the steady growth in loan financing compared to the loan size a year ago.

The segment registered a higher pre-tax profit of RM3.06 million for the current quarter in comparison with RM1.39 million for the corresponding quarter, bolstered by relatively higher loan financing as compared to the corresponding quarter.

B3. Profit before tax

Profit before tax is arrived at after (charging)/crediting, amongst others, the items as follows:

	Current Quarter Ended 31 March 2023 RM'000	Corresponding Quarter Ended 31 March 2022 RM'000	Current Year-To-Date Ended 31 March 2023 RM'000	Corresponding Year-To-Date Ended 31 March 2022 RM'000
Interest income	12	8	12	8
Dividend income	1	9	1	9
Interest expense	(58)	(46)	(58)	(46)
Depreciation of:				
- property, plant and equipment	(545)	(547)	(545)	(547)
- right-of-use assets	(61)	(77)	(61)	(77)
Amortisation of intangible assets	-	(9)	-	(9)
Inventories:				
- written off	(55)	(57)	(55)	(57)
- written down	(104)	(155)	(104)	(155)
Reversal of/(Allowance for) impairment loss on receivables	168	(28)	168	(28)
Reversal of inventories written down	39	194	39	194
Share of loss of associate	(21)	-	(21)	-
Employee benefit expenses under Share Issuance Scheme	-	(200)	-	(200)
Gain/(loss) from foreign exchange:				
- realised	(35)	(1)	(35)	(1)
- unrealised	44	13	44	13

B4. Material changes in the current quarter's results compared to the results of the preceding quarter

	Current Quarter Ended 31 March 2023 RM'000	Preceding Quarter Ended 31 December 2022 RM'000	Variance	
			RM'000	%
Revenue	23,035	17,036	5,999	35.21
Profit before tax	2,036	1,637	399	24.37

The Group posted 35.21% higher in revenue of RM23.04 million for the current quarter compared to RM17.04 million for the preceding quarter, mainly driven by a higher export sale of edible bird's nest and a steady growth in loan financing business in the current quarter.

The Group registered a higher pre-tax profit of approximately RM2.04 million despite having a lower operating profit in the current quarter, compared to RM1.64 million in the preceding quarter, mainly due to lower selling and distribution expenses and other operating expenses incurred in the current quarter.

B5. Prospects

Animal health segment will continue to explore overseas market by promoting a wider range of products and technical supports as well as exploring new distributorship aside from the existing networks. As local market has yet to recover fully from the threat posed by African Swine Fever (ASF) on swine farms, more focusing will be placed on poultry market especially on feed and food hygiene aspects. TCM segment foresees a softer demand for its products and export of bird's nest in the coming quarter, however operation currently still maintains around a 70% capacity. Loan financing business is expected to grow moderately in the coming quarter in view of the soft sentiment in the current market.

B6. Profit forecast and profit guarantee

Pursuant to the share sale agreement dated 12 January 2021 between Finsource Credit (M) Sdn Bhd ("Finsource") and the Company ("purchaser"), the guarantors have given a guaranteed profit of not less than RM2 million based on audited profit after tax ("PAT") of Finsource for the financial years ended 31 December 2021 and 2022. As a security for the performance of the guaranteed profit, the guarantors have placed with the stakeholder an amount of Consideration Shares of value equivalent to the guaranteed profit.

The guarantors have achieved the profit guarantee with reference to the audited financial statements presented for the financial years ended 31 December 2021 and 2022 with PAT of RM0.96 million and RM5.08 million, respectively.

B7. Income tax expense

	Current Quarter Ended 31 March 2023 RM'000	Corresponding Quarter Ended 31 March 2022 RM'000	Current Year-To-Date Ended 31 March 2023 RM'000	Corresponding Year-To-Date Ended 31 March 2022 RM'000
<u>Income tax expense:</u>				
Current financial year	799	856	799	856
Over-provision in the previous year	-	(1)	-	(1)
	799	855	799	855
<u>Deferred tax expense:</u>				
Over-provision in the previous year	(10)	(18)	(10)	(18)
	(10)	(18)	(10)	(18)
Total	789	837	789	837

B8. Status of Corporate Proposal

There were no corporate proposals which have already announced but not yet completed as at the reporting date.

Utilisation of proceeds raised from Private Placement

The status of the utilisation as at 31 March 2023 is set out below:

	Proceeds RM'000	Utilised RM'000	Unutilised RM'000	Intended timeframe from the listing date*
<u>Proposed utilisation:</u>				
Expansion of money lending business	17,252	17,252	-	within 9 months
Expenses for new animal health products	863	466	397	within 18 months
Working capital	2,465	2,465	-	within 12 months
Estimated expenses	197	197	-	immediate
Total	20,777	20,380	397	

* Listing date of placement shares on 23/11/2021 and 31/12/2021 for tranche 1 and 2, respectively

B8. Status of Corporate Proposal (Cont'd)

Share Issuance Scheme, expiring on 15 April 2026

The details of the total number of share options exercisable, cancelled, exercised and the balance as at the reporting date are as follows.

	Share option	Exercise price	No. of share option exercisable	No. of share option lapsed	No. of share option exercised	Balance of share option exercisable
		RM	'000	'000	'000	'000
Directors	A	0.1395	77,670	-	-	77,670
Employees	A	0.1395	1,730	-	136	1,594
Employees	B	0.1772	419	-	59	360
		Total	79,819	-	190	79,624

79,624,000 share options are exercisable, while 21,783,200 share options are non-exercisable subject to performance criteria to be fulfilled by employees over the option tenure, giving a total outstanding number of share options of 101,407,200 as at the reporting date.

B9. Loans and borrowings

The term loan is repayable in 310 monthly instalments of RM24,335 equal monthly instalments, effective from September 2019.

	31 March 2023	31 March 2022
	RM'000	RM'000
<u>Term loans:</u>		
Current liabilities	130	135
Non-current liabilities	4,459	4,579
Total	4,589	4,714

B10. Material Litigation

As at the date of this announcement, neither the Company nor any of its subsidiaries is engaged in any material litigation and arbitration either as plaintiff or defendant, which has a material effect on the financial position of the Company or its subsidiaries and the Directors are not aware of any proceedings pending or threatened or of any facts likely to give rise to any proceedings which might materially and adversely affect the financial position or business of the Company or its subsidiaries, save for the following legal action.

B11. Dividend declared or recommended

No dividend was declared for the current quarter under review.

B12. Disclosure of nature of outstanding derivatives

There were no outstanding derivatives as at reporting period.

B13. Disclosure of gains/losses arising from fair value changes of financial liabilities

There were no gains or losses arising from fair value changes of financial liabilities as at the reporting period.

B14. Earnings per ordinary share

Basic earnings per ordinary share is calculated based on consolidated profit for the financial period attributable to equity holders of the Company over the weighted average number of ordinary shares in issue excluding 15,937,300 treasury shares (2021: 6,281,400) during the financial period.

	Current Quarter Ended 31 March 2023	Corresponding Quarter Ended 31 March 2022	Current Year-To-Date Ended 31 March 2023	Corresponding Year-To-Date Ended 31 March 2022
Profit attributable to equity holders of the Company (RM'000)	1,074	741	1,074	741
Weighted average number of ordinary shares in issue excluding treasury shares ('000)	707,064	614,517	707,064	614,517
Basic earnings per ordinary share (sen)	0.15	0.12	0.15	0.12
Weighted average number of ordinary shares in issue excluding treasury shares after adjusting for the effects all dilutive potential ordinary shares ('000)	732,894	652,030	732,894	652,030
Diluted earnings per ordinary share (sen)	0.15	0.11	0.15	0.11

Diluted earnings per ordinary share is calculated based on consolidated profit for the financial period attributable to equity holders of the Company over the weighted average of ordinary shares in issue excluding treasury shares after adjusting for the effects of all dilutive potential ordinary shares.

This quarterly report for the financial period ended 31 March 2023 has been reviewed and approved by the Board of Directors of Sunzen Biotech Berhad for release to Bursa Securities.

Date: 26 May 2023